← TG Therapeutics, Inc. (TGTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
TG Therapeutics, Inc. (TGTX)
Pharmaceutical Preparations · market cap $8.6B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
TG Therapeutics (TGTX) is a commercial-stage pharmaceutical company with a $9B market cap and 374 employees, generating $616M in revenue and $447M in net income in 2025. The company operates across multiple sclerosis and oncology, with a diversified pipeline including Phase 3 assets in RMS (Teriflunomide), Non-Hodgkin's Lymphoma (Ublituximab), and CLL (Ibrutinib). The two highest-impact upcoming catalysts are Phase 3 Ublituximab readouts flagged for September and December 2026.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 3 · Ublituximabimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis (RMS) |
| Umbralisib | Phase 2 | Marginal Zone Lymphoma |
| Ublituximab | Phase 3 | Non-Hodgkins Lymphoma |
Price & technical context
3-month
-3.3%
6-month
+60.0%
12-month
+46.4%
52-wk range
$26.94–$59.06
vs 50-day MA
-0.1%
vs 200-day MA
+29.9%
Realized vol
44.9%
Max drawdown
-42.0%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TGTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.